Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide

Clinical Immunology

Volumn 138, Issue 2, 2011, Pages 201-211

  Huang, Mei Chuan ^a   Greig, Nigel H ^b   Luo, Weiming ^b   Tweedie, David ^b   Schwartz, Janice B ^a   Longo, Dan L ^b   Ferrucci, Luigi ^b   Ershler, William B ^b   Goetzl, Edward J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Apoptosis; Chemotaxis; Cytokines; Human; Proliferation; T lymphocytes

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; LENALIDOMIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SPHINGOSINE 1 PHOSPHATE; T LYMPHOCYTE RECEPTOR; THALIDOMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; CHEMOTAXIS; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SENESCENCE; SURVIVAL; T LYMPHOCYTE;

ADULT; AGED; AGING; BCL-X PROTEIN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CCL21; CHEMOTAXIS; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MONOCYTES; T-LYMPHOCYTES; THALIDOMIDE; YOUNG ADULT;

EID: 79251597893     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.11.002     Document Type: Article

References (49)

1. Dorshkind K., Montecino-Rodriguez E., Signer R.A. The ageing immune system: is it ever too old to become young again?. Nat. Rev. Immunol. 2009, 9:57-62.
2. Caruso C., Buffa S., Candore G., Colonna-Romano G., Dunn-Walters D., Kipling D., Pawelec G. Mechanisms of immunosenescence. Immun. Ageing 2009, 6:10.
3. Johnson K.M., Owen K., Witte P.L. Aging and developmental transitions in the B cell lineage. Int. Immunol. 2002, 14:1313-1323.
4. Johnson S.A., Cambier J.C. Ageing, autoimmunity and arthritis: senescence of the B cell compartment - implications for humoral immunity. Arthritis Res. Ther. 2004, 6:131-139.
5. Agrawal A., Agrawal S., Cao J.N., Su H., Osann K., Gupta S. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J. Immunol. 2007, 178:6912-6922.
6. Agrawal A., Agrawal S., Tay J., Gupta S. Biology of dendritic cells in aging. J. Clin. Immunol. 2008, 28:14-20.
7. Gomez C.R., Nomellini V., Faunce D.E., Kovacs E.J. Innate immunity and aging. Exp. Gerontol. 2008, 43:718-728.
8. Agius E., Lacy K.E., Vukmanovic-Stejic M., Jagger A.L., Papageorgiou A.P., Hall S., Reed J.R., Curnow S.J., Fuentes-Duculan J., Buckley C.D., Salmon M., Taams L.S., Krueger J., Greenwood J., Klein N., Rustin M.H., Akbar A.N. Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J. Exp. Med. 2009, 206:1929-1940.
9. Wack A., Cossarizza A., Heltai S., Barbieri D., D'Addato S., Fransceschi C., Dellabona P., Casorati G. Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int. Immunol. 1998, 10:1281-1288.
10. Fagnoni F.F., Vescovini R., Passeri G., Bologna G., Pedrazzoni M., Lavagetto G., Casti A., Franceschi C., Passeri M., Sansoni P. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000, 95:2860-2868.
11. Gupta S., Bi R., Su K., Yel L., Chiplunkar S., Gollapudi S. Characterization of naive, memory and effector CD8+ T cells: effect of age. Exp. Gerontol. 2004, 39:545-550.
12. Naylor K., Li G., Vallejo A.N., Lee W.W., Koetz K., Bryl E., Witkowski J., Fulbright J., Weyand C.M., Goronzy J.J. The influence of age on T cell generation and TCR diversity. J. Immunol. 2005, 174:7446-7452.
13. Gupta S., Agrawal A., Agrawal S., Su H., Gollapudi S. A paradox of immunodeficiency and inflammation in human aging: lessons learned from apoptosis. Immun. Ageing 2006, 3:5.
14. Kilpatrick R.D., Rickabaugh T., Hultin L.E., Hultin P., Hausner M.A., Detels R., Phair J., Jamieson B.D. Homeostasis of the naive CD4+ T cell compartment during aging. J. Immunol. 2008, 180:1499-1507.
15. Goetzl E.J., Huang M.C., Kon J., Patel K., Schwartz J.B., Fast K., Ferrucci L., Madara K., Taub D.D., Longo D.L. Gender specificity of altered human immune cytokine profiles in aging. FASEB J. 2010, 24:3580-3589.
16. Gregg R., Smith C.M., Clark F.J., Dunnion D., Khan N., Chakraverty R., Nayak L., Moss P.A. The number of human peripheral blood CD4+ CD25 high regulatory T cells increases with age. Clin. Exp. Immunol. 2005, 140:540-546.
17. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
18. Marko M.G., Ahmed T., Bunnell S.C., Wu D., Chung H., Huber B.T., Meydani S.N. Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation. J. Immunol. 2007, 178:1443-1449.
19. Lages C.S., Suffia I., Velilla P.A., Huang B., Warshaw G., Hildeman D.A., Belkaid Y., Chougnet C. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J. Immunol. 2008, 181:1835-1848.
20. Huang M.C., Patel K., Taub D.D., Longo D.L., Goetzl E.J. Human CD4-8- T cells are a distinctive immunoregulatory subset. FASEB J. 2010, 24:2558-2566.
21. Monteiro J., Batliwalla F., Ostrer H., Gregersen P.K. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J. Immunol. 1996, 156:3587-3590.
22. Effros R.B., Dagarag M., Spaulding C., Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol. Rev. 2005, 205:147-157.
23. Gupta S., Gollapudi S. TNF-alpha-induced apoptosis in human naive and memory CD8+ T cells in aged humans. Exp. Gerontol. 2006, 41:69-77.
24. Rea I.M., Stewart M., Campbell P., Alexander H.D., Crockard A.D., Morris T.C. Changes in lymphocyte subsets, interleukin 2, and soluble interleukin 2 receptor in old and very old age. Gerontology 1996, 42:69-78.
25. Caruso C., Candore G., Cigna D., DiLorenzo G., Sireci G., Dieli F., Salerno A. Cytokine production pathway in the elderly. Immunol. Res. 1996, 15:84-90.
26. Corral L.G., Muller G.W., Moreira A.L., Chen Y., Wu M., Stirling D., Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol. Med. 1996, 2:506-515.
27. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., Patterson R.T., Stirling D.I., Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 1999, 163:380-386.
28. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., Kumar S., Chauhan D., Treon S.P., Richardson P., Anderson K.C. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 2005, 128:192-203.
29. Reddy N., Hernandez-Ilizaliturri F.J., Deeb G., Roth M., Vaughn M., Knight J., Wallace P., Czuczman M.S. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 2008, 140:36-45.
30. Schafer P.H., Gandhi A.K., Loveland M.A., Chen R.S., Man H.W., Schnetkamp P.P., Wolbring G., Govinda S., Corral L.G., Payvandi F., Muller G.W., Stirling D.I. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther. 2003, 305:1222-1232.
31. Payvandi F., Wu L., Naziruddin S.D., Haley M., Parton A., Schafer P.H., Chen R.S., Muller G.W., Hughes C.C., Stirling D.I. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. J. Interferon Cytokine Res. 2005, 25:604-616.
32. Galustian C., Meyer B., Labarthe M.C., Dredge K., Klaschka D., Henry J., Todryk S., Chen R., Muller G., Stirling D., Schafer P., Bartlett J.B., Dalgleish A.G. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 2009, 58:1033-1045.
33. Xu Y., Li J., Ferguson G.D., Mercurio F., Khambatta G., Morrison L., Lopez-Girona A., Corral L.G., Webb D.R., Bennett B.L., Xie W. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009, 114:338-345.
34. LeBlanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., Mitsiades C., Cheema P., Chauhan D., Richardson P.G., Anderson K.C., Munshi N.C. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103:1787-1790.
35. Graler M.H., Huang M.C., Watson S., Goetzl E.J. Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J. Immunol. 2005, 174:1997-2003.
36. Zhu X., Giordano T., Yu Q.S., Holloway H.W., Perry T.A., Lahiri D.K., Brossi A., Greig N.H. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J. Med. Chem. 2003, 46:5222-5229.
37. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 1998, 187:1885-1892.
38. Tohnya T.M., Hwang K., Lepper E.R., Fine H.A., Dahut W.L., Venitz J., Sparreboom A., Figg W.D. Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 811:135-141.
39. Dahut W.L., Aragon-Ching J.B., Woo S., Tohnya T.M., Gulley J.L., Arlen P.M., Wright J.J., Ventiz J., Figg W.D. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J. Clin. Pharmacol. 2009, 49:650-660.
40. Haynes L., Linton P.J., Eaton S.M., Tonkonogy S.L., Swain S.L. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J. Exp. Med. 1999, 190:1013-1024.
41. D.M. Mitchell, E.V. Ravkov, M.A. Williams, Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J. Immunol. 184 (2010) 6719-6730.
42. Gillis S., Kozak R., Durante M., Weksler M.E. Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J. Clin. Invest. 1981, 67:937-942.
43. Swain S., Clise-Dwyer K., Haynes L. Homeostasis and the age-associated defect of CD4 T cells. Semin. Immunol. 2005, 17:370-377.
44. Nelson B.H. IL-2, regulatory T cells, and tolerance. J. Immunol. 2004, 172:3983-3988.
45. Brenner D., Krammer P.H., Arnold R. Concepts of activated T cell death. Crit. Rev. Oncol. Hematol. 2008, 66:52-64.
46. Li J., Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na(+)/H(+)-antiport. J. Biol. Chem. 1995, 270:3203-3211.
47. Devireddy L.R., Green M.R. Transcriptional program of apoptosis induction following interleukin 2 deprivation: identification of RC3, a calcium/calmodulin binding protein, as a novel proapoptotic factor. Mol. Cell. Biol. 2003, 23:4532-4541.
48. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., Sran P., Yaffe A., Goldman C.K., Waldmann T.A., Whitcup S.M. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl Acad. Sci. USA 1999, 96:7462-7466.
49. Bielekova B., Richert N., Howard T., Blevins G., Markovic-Plese S., McCartin J., Frank J.A., Wurfel J., Ohayon J., Waldmann T.A., McFarland H.F., Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl Acad. Sci. USA 2004, 101:8705-8708.